Nanobiotix (NBTX) said Monday its JNJ-1900 drug candidate showed a median overall survival of 23 months for certain patients with pancreatic cancer in a phase 1 study.
A historical review of 144 patients with locally advanced pancreatic cancer treated at the same center showed a median overall survival of 19.2 months, the company said.
The drug, jointly developed with Johnson & Johnson (JNJ) subsidiary Janssen Pharmaceutica, also showed a favorable safety profile, Nanobiotix said.
The company added that the results prompted investigators to recommend further evaluation in a randomized study. The US Food and Drug Administration has also cleared researchers to expand the study to include a new cohort that has already recruited and dosed its first patient, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.